Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bile duct neoplasms

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    26 result(s) found for: Bile duct neoplasms. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2020-002605-25 Sponsor Protocol Number: AIO-HEP-0120 Start Date*: 2021-03-24
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: Neoadjuvant Bintrafusp alfa in patients with resectable biliary tract cancer (NEOBIL)
    Medical condition: Treatment-naive subjects with a diagnosis of resectable biliary tract cancer, confirmed by histopathology
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10004593 Bile duct cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10004597 Bile duct cancer resectable LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10004598 Bile duct carcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007289 Carcinoma bile duct LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10004601 Bile duct carcinoma resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-017428-17 Sponsor Protocol Number: 20091105 Start Date*: 2010-05-31
    Sponsor Name:AZIENDA OSPEDALIERA ORDINE MAURIZIANO
    Full Title: A Phase II Randomized Clinical Trial of Panitumumab plus Gemcitabine and Oxaliplatin (GEMOX) versus GEMOX alone as First Line Treatment in Advanced Biliary Tract Adenocarcinoma
    Medical condition: advanced intrahepatic colangiocarcinoma and extrahepatic biliary adenocarcinoma including gallbladder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008594 LLT
    9.1 10025943 LLT
    9.1 10061239 LLT
    9.1 10022789 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-003217-11 Sponsor Protocol Number: NL82304.058.22 Start Date*: 2023-02-24
    Sponsor Name:Leiden University Medical Center
    Full Title: Standard versus Pre-emptive Antibiotic Treatment to Reduce the Rate of Infectious Outcomes after Whipple procedure (SPARROW): a multicenter, randomized controlled trial
    Medical condition: Pancreatic head malignancy
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033614 Pancreatic carcinoma resectable LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026319 Malignant neoplasm of pancreatic duct LLT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008597 Cholangiocarcinoma resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004415-39 Sponsor Protocol Number: TO-TAS0728-101 Start Date*: 2019-02-05
    Sponsor Name:Taiho Oncology, Inc.
    Full Title: A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF TAS0728, AN ORAL COVALENT BINDING INHIBITOR OF HER2, IN SUBJECTS WITH ADVANCED SOLID TUMORS W...
    Medical condition: Urothelial cancer with HER2 or HER3 mutation Biliary tract cancer with HER2 or HER3 mutation Breast cancer with HER2 or HER3 mutation Breast cancer with HER2 amplification/overexpression as per AS...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10004593 Bile duct cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077840 Urothelial cancer of renal pelvis LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10079440 Non-squamous non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003323-30 Sponsor Protocol Number: EORTC-1607-GITCG Start Date*: 2020-01-20
    Sponsor Name:European Organisation for the Research and Treatment of Cancer (EORTC)
    Full Title: Open-label first line, single-arm phase II study of CisGem combined with pembrolizumab in patients with advanced or metastatic biliary tract cancer
    Medical condition: Non-resectable or recurrent/metastatic BTC
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10004655 Biliary carcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10004593 Bile duct cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10004613 Bile duct neoplasms malignant HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019815 Hepatobiliary neoplasms malignant and unspecified HLGT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2013-004385-34 Sponsor Protocol Number: ICM_2013/09 Start Date*: 2014-05-27
    Sponsor Name:Institut régional du Cancer - Montpellier - Val d'Aurelle
    Full Title: Activity of Regorafenib in combination with modified Gemcitabine - Oxaliplatin Chemotherapy (mGEMOX) in patients with advanced Biliary Tract Cancer (BTC): A Phase Ib-II trial
    Medical condition: advanced Biliary Tract Cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055111 Biliary cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-005796-34 Sponsor Protocol Number: CC-GEMSO-2007 Start Date*: 2008-03-19
    Sponsor Name:Universität Mainz, I. Medizinische Klinik und Poliklinik
    Full Title: A randomized, double-blind, multicenter phase II trial with gemcitabine plus sorafenib versus gemcitabine plus placebo in patients with chemo-naive advanced or metastatic adenocarcinoma of the bili...
    Medical condition: Patients with Adenocarcinoma of the gallbladder or intrahepatic bile ducts or histologically proven hepatic metastases of an earlier resected and histologically proven biliary tract cancer
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008593 Cholangiocarcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-003056-12 Sponsor Protocol Number: D4200L00007 Start Date*: 2008-05-23
    Sponsor Name:ASTRAZENECA
    Full Title: A RANDOMISED, MULTICENTRE, PHASE II, PARALLEL-GROUP TRIAL OF VANDETANIB MONOTHERAPY OR VANDETANIB IN COMBINATION WITH GEMCITABINE VERSUS GEMCITABINE PLUS VANDETANIB MATCHING PLACEBO IN SUBJECTS WIT...
    Medical condition: ADVANCED BILIARY TRACT CANCER
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019815 Hepatobiliary neoplasms malignant and unspecified HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-004953-96 Sponsor Protocol Number: JTX-4014-202 Start Date*: 2020-06-24
    Sponsor Name:Jounce Therapeutics, Inc.
    Full Title: Phase 2 Study of PD-1 Inhibitor JTX-4014 Alone and in Combination with Vopratelimab, an ICOS Agonist, in Biomarker-selected Subjects with Metastatic NSCLC After One Prior Platinum-containing Regimen
    Medical condition: Metastatic Non Small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed) BG (Completed) HR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004118-84 Sponsor Protocol Number: ONC-2016-001 Start Date*: 2017-04-21
    Sponsor Name:IRCCS ISTITUTO CLINICO HUMANITAS
    Full Title: A multicenter, phase I-II trial of gemcitabine plus oxaliplatin and nbb-paclitaxel in subjects with advanced (unresectable or metastatic) biliary tract cancer (gallbladder cancer, cancer of the ext...
    Medical condition: Advanced (unresectable or metastatic) biliary tract cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073073 Hepatobiliary cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002798-12 Sponsor Protocol Number: 14.07 Start Date*: 2014-09-24
    Sponsor Name:Odense University Hospital
    Full Title: Neoadjuvant chemotherapy in patients with biliary tract carcinomas - A Nordic phase II study
    Medical condition: Patients with resectable intra- or extrahepatic biliary tract carcinomas.
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10025734 Malignant neoplasm of biliary tract, part unspecified LLT
    17.0 100000004864 10028982 Neoplasm biliary tract LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-006302-42 Sponsor Protocol Number: 09/H0604/36 Start Date*: 2009-05-13
    Sponsor Name:The University of Oxford
    Full Title: A Phase II study in patients with locally advanced pancreatic carcinoma: ARC-II – Akt-inhibition by Nelfinavir plus chemoradiation with gemcitabine and cisplatin
    Medical condition: borderline resectable or unresectable pancreatic carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033611 Pancreatic carcinoma non-resectable PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033600 Pancreatic adenocarcinoma non-resectable LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033606 Pancreatic cancer non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-001538-25 Sponsor Protocol Number: AIO-HEP-0117 Start Date*: 2018-03-12
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: A randomized phase II trial of durvalumab and tremelimumab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-naïve patients with cholangio- and gallbl...
    Medical condition: advanced, unresectable and/or metastatic cholangio- and gallbladder carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10017617 Gallbladder cancer non-resectable LLT
    20.0 100000004864 10017620 Gallbladder carcinoma LLT
    20.0 100000004864 10025941 Malignant neoplasm of gallbladder and extrahepatic bile ducts LLT
    21.1 100000004864 10025940 Malignant neoplasm of gallbladder LLT
    20.0 100000004864 10007426 Carcinoma of gallbladder LLT
    21.1 100000004864 10017622 Gallbladder carcinoma non-resectable LLT
    21.1 100000004864 10025943 Malignant neoplasm of gallbladder and extrahepatic bile ducts non-resectable LLT
    21.1 100000004864 10077744 Adenocarcinoma of gallbladder metastatic LLT
    21.1 100000004864 10077847 Gallbladder adenocarcinoma metastatic LLT
    20.0 100000004864 10008594 Cholangiocarcinoma non-resectable LLT
    21.1 100000004864 10077846 Cholangiocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003775-62 Sponsor Protocol Number: KFE17.16 Start Date*: 2018-05-01
    Sponsor Name:Odense University Hospital
    Full Title: FOLFIRINOX followed by local therapy (resection, RT and/or IRE) in patients with locally advanced pancreatic cancer (LAPC). A Nordic phase II study.
    Medical condition: Locally advanced pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033606 Pancreatic cancer non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-003787-24 Sponsor Protocol Number: PM-CARE-PNRR-MAD-2022-12375905 Start Date*: 2023-04-20
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: Precision Medicine in patients with unresectable CholAngiocarcinoma; RadioEmbolization and combined biological therapy (Single arm, multicenter phase II study investigating the efficacy and safety...
    Medical condition: Unresectable intrahepatic cholangiocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073077 Intrahepatic cholangiocarcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008593 Cholangiocarcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-018850-11 Sponsor Protocol Number: MHH_CCA_AG54 Start Date*: 2011-04-15
    Sponsor Name:Medizinische Hochschule Hannover (MHH)
    Full Title: Panitumumab in combination with cisplatin/gemcitabine chemotherapy in patients with cholangiocarcinomas - a randomized clinical phase II study - PiCCA Study
    Medical condition: cholangiocarcinoma / gall bladder carcinoma
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017620 Gallbladder carcinoma LLT
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008593 Cholangiocarcinoma LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-004826-27 Sponsor Protocol Number: GI1863 Start Date*: 2019-04-11
    Sponsor Name:Department of Oncology, Herlev & Gentofte Hospital
    Full Title: A Single Center, Randomized, Phase II Study of the combination of Cisplatin and Gemcitabine with or without Tocilizumab, an IL-6R inhibitor, as first-line treatment in patients with locally advance...
    Medical condition: First-line treatment in patients with locally advanced or metastatic biliary tract cancer, inoperable due to extension of the disease.
    Disease: Version SOC Term Classification Code Term Level
    25.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008594 Cholangiocarcinoma non-resectable LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008596 Cholangiocarcinoma recurrent LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074878 Hilar cholangiocarcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074879 Extrahepatic cholangiocarcinoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077846 Cholangiocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-004938-38 Sponsor Protocol Number: ADVANCE2020 Start Date*: 2021-12-08
    Sponsor Name:Frankfurter Institut für Klinische Krebsforschung IKF GmbH
    Full Title: ADVANCE: A phase II single-arm, open-label study of Atezolizumab and Derazantinib for patients with advanced intrahepatic cholangiocarcinoma with FGFR2 fusions/rearrangements
    Medical condition: Advanced non-resectable intrahepatic cholangiocarcinoma with positively confirmed FGFR2 fusion/rearrangements via NGS-Analysis
    Disease: Version SOC Term Classification Code Term Level
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008593 Cholangiocarcinoma PT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008594 Cholangiocarcinoma non-resectable LLT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073077 Intrahepatic cholangiocarcinoma LLT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077846 Cholangiocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-002565-22 Sponsor Protocol Number: LOKON002 Start Date*: 2017-12-21
    Sponsor Name:Lokon Pharma AB
    Full Title: Phase I/II Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer
    Medical condition: Colorectal, ovarian, pancreatic, gallbladder and bile duct cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007050 Cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2020-003759-14 Sponsor Protocol Number: GO42661 Start Date*: 2021-01-21
    Sponsor Name:F. Hoffman-La Roche Ltd.
    Full Title: A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB WITH OR WITHOUT BEVACIZUMAB IN COMBINATION WITH CISPLATIN PLUS GEMCITABINE IN PATIENTS WITH UNTREATED, ADVANCED BILIAR...
    Medical condition: Biliary tract cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008593 Cholangiocarcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001141 Adenocarcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 27 20:52:53 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA